Qing Wang

Dr. Qing Wang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
QLQiaowei Lin
Qiaowei Lin
LLLiang Li
Liang Li
QWQing Wang
Qing Wang
XWXiao Wang
Xiao Wang
YYYang You
Yang You
XGXi Guo
Xi Guo
Background: As one of the important components of immunotherapies, mRNA vaccines have displayed promising clinical outcomes in solid tumors. Nonetheless, their efficacy remains unclear in pancreatic adenocarcinoma (PAAD). Given the interaction of pyroptosis with anticancer immunity, our study aims to identify pyroptosis-related antigens for mRNA vaccine development and discern eligible candidates for vaccination. Methods: Utilizing gene expression data from TCGA and ICGC, we integrated RNA-seq data and compared genetic alterations through cBioPortal. Differential gene expressions were integrated using GEPIA. Relationships between immune cell abundance and tumor antigens were analyzed and visualized via TIMER. WGCNA facilitated the clustering of pyroptosis-related genes, identification of hub genes, and pathway enrichment analyses. Pyroptosis landscape was depicted through graph learning-based dimensional reduction. Results: Four overexpressed and mutant pyroptosis-related genes associated with poor prognosis were identified as potential antigens for mRNA vaccines in PAAD, including ANO6, PAK2, CHMP2B, and RAB5A. These genes displayed positive associations with antigen-presenting cells. PAAD patients were stratified into three pyroptosis subtypes. Notably, the PS3 subtype, characterized by a lower mutation count and TMB, exhibited “cold” immunological traits and superior survival compared to other subtypes. The pyroptosis landscape exhibited considerable heterogeneity among individuals. Furthermore, the turquoise module emerged as an independent prognostic indicator and patients with high expressions of hub genes might not be suitable candidates for mRNA vaccination. Conclusions: In PAAD, ANO6, PAK2, CHMP2B, and RAB5A are prospective pyroptosis-related antigens for mRNA vaccine development, which holds potential benefits for patients classified as PS3 and those with diminished hub gene expressions, providing insights into personalized mRNA vaccine strategies.

26 July 2023 in Research Square
Verified
Preprint
Open access
PDF file
QWQing Wang
Qing Wang
HWHe Wang
He Wang
CYChangjie Yang
Changjie Yang
XWXiao Wang
Xiao Wang
JMJiaxiang Meng
Jiaxiang Meng
Background Hepatocellular carcinoma (HCC) is a significant contributor to cancer-related mortality, ranking third in this regard. The epigenetic regulation of RNA N6-methyladenosine (m6A) modification in HCC has garnered considerable attention. This study utilized bioinformatics analysis and biologically engineered mice models to explore the immune and prognostic role of m6A modification in HCC. Methods We systematically analyzed genetic alterations, expression patterns, signaling pathways, prognostic features, and immunotherapy efficacy of the 21 m6A regulators in HCC as obtained from the Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO, GSE14520, GSE76427), and International Cancer Genome Consortium (IGCG) database; Unsupervised clustering, gene set variation analysis (GSVA), LASSO-COX regression, multivariate Cox regression, Nomogram, receiver operating characteristic (ROC) analysis, TIMER 2.0 and ImmuCellAI were used to perform the above analysis. Our analysis was verified with Mettl3F/FAlbumin-cre (liver-specific knockout, LKO) mice to establish a chemo-induced HCC model. The tumor immune microenvironment was analyzed with immunohistochemistry, immunofluorescence staining, and flow cytometry. Results The genetic alteration of the m6A modification gene set exhibited a correlation with reduced progression-free survival, diminished abundance of macrophage cells, and a lower score for immune cell infiltration. The cluster characterized by lower expression of the m6A gene set was linked to a more favorable overall survival (OS) and immune signaling, including IL2-STAT5, IL6-STAT3, IFN-gamma, and IFN-alpha signaling. Notably, the cluster with higher expression of m6A was associated with a higher homologous recombination deficiency (HRD) score and tumor mutational burden (TMB) score. Results of LASSO COX and the nomogram model underscored the significant contribution of METTL3 in the prognosis and ICB therapy of HCC. The results of Mettl3 LKO mice confirmed that Mettl3 LKO acted as a "rheostat" in the progression of HCC by regulating the mouse liver's myeloid-related innate and adaptive immune landscape. Conclusions In this study, we characterized the genetic, immune, and clinic landscape of the m6A gene set in HCC development and unveiled METTL3 as a molecular biomarker in epigenetic-related progress and ICB therapy of HCC from both informatics database analysis and engineered mice model.